Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Deakin

Showing results (81-90 of 85) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 85 results.
Trials|November 11, 2017
A randomised, double-blind, placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at-risk mental states (NAYAB): study protocolInti Qurashi, Imran B Chaudhry, Ameer B Khoso, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 14, 2017
Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol DependenceAnna Murphy, Liam J Nestor, John McGonigle, et al.
Translational Psychiatry|March 8, 2017
Effects of naltrexone are influenced by childhood adversity during negative emotional processing in addiction recoveryG Savulich, R Riccelli, L Passamonti, et al.
Cell|November 25, 2021
From structure to clinic: Design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer's diseaseAlastair J H Brown, Sophie J Bradley, Fiona H Marshall, et al.
Molecular Psychiatry|April 5, 2017
Collaborative meta-analysis finds no evidence of a strong interaction between stress and 5-HTTLPR genotype contributing to the development of depressionR C Culverhouse, N L Saccone, A C Horton, et al.
Pageof 9

Showing results (81-90 of 85) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 85 results.
Trials|November 11, 2017
A randomised, double-blind, placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at-risk mental states (NAYAB): study protocolInti Qurashi, Imran B Chaudhry, Ameer B Khoso, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 14, 2017
Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol DependenceAnna Murphy, Liam J Nestor, John McGonigle, et al.
Translational Psychiatry|March 8, 2017
Effects of naltrexone are influenced by childhood adversity during negative emotional processing in addiction recoveryG Savulich, R Riccelli, L Passamonti, et al.
Cell|November 25, 2021
From structure to clinic: Design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer's diseaseAlastair J H Brown, Sophie J Bradley, Fiona H Marshall, et al.
Molecular Psychiatry|April 5, 2017
Collaborative meta-analysis finds no evidence of a strong interaction between stress and 5-HTTLPR genotype contributing to the development of depressionR C Culverhouse, N L Saccone, A C Horton, et al.
Pageof 9